Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland

Clinical Implementation of DPYD Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland

The implementation of pharmacogenetic testing into clinical practice has been a slow process so far. Here, we review the implementation of pre-treatment testing of dihydropyrimidine dehydrogenase gene (DPYD) risk variants to prevent early-onset fluoropyrimidine (FP)-related toxicity in cancer patien...

Full description

Bibliographic Details
Main Authors: Ursina B. M. Begré, Markus Jörger, Stefan Aebi, Ursula Amstutz, Carlo R. Largiadèr
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-05-01
Series:Frontiers in Pharmacology
Subjects:
adverse drug reactions
chemotherapy
clinical implementation
dihydropyrimidine dehydrogenase
DPYD
early adopter
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2022.885259/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2022.885259/full

Similar Items